Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

Novartis AG (NYSE: NVS) shares are trading higher after the company reported second-quarter EPS and sales results higher from last year.

Novartis Trades Higher On Q2 Earnings, Guidance Raise

Novartis  boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors.

Novartis raises full-year targets, aims to settle U.S. lawsuit

Novartis  Chief Executive Vas Narasimhan set aside $700 million to settle a U.S. doctor bribery lawsuit, as the Swiss drugmaker seeks to close the chapter on allegedly aggressive business practices that exposed it to litigation risks.

Novartis CEO sets aside $700 million to settle doctor bribery lawsuit

Novartis earnings topped views, while Q2 revenue was in line. The Swiss drug giant raised some 2019 guidance.

Novartis Earnings Top; Swiss Drug Giant's Sales In Line

Novartis  lifted full-year sales and profit targets on Thursday, helped by innovative medicine sales and as the Swiss drugmaker's slimmed-down Sandoz generics unit saw accelerating revenue in markets outside the United States.

Novartis raises 2019 guidance, helped by Sandoz generics unit

Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%.

Should You Pick Up Novartis (NVS) Before Q2 Earnings?

Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.

Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?

The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.

Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA

Adamis Pharmaceuticals

Sandoz recently announced the U.S.retail launch of SYMJEPI in the middle of a Epipen shortage around the country.

Sandoz And Adamis Pharmaceuticals Will Benefit From Epipen Shortage

Amgen

Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN) announced the failure of a candidate drug treatment for Alzheimer's disease.

More bad news for Alzheimer's patients

Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

Amgen & Novartis' Alzheimer Studies End in Another Failure

A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development.

Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug

Amgen Inc. AMGN, -2.34% and Novartis AG NVS, -1.15% announced Thursday afternoon that they will discontinue a study into a potential Alzheimer's disease prevention therapy after patients in the study showed worsening conditions.

Amgen and Novartis drop Alzheimer's-prevention study after patients worsened

Cenovus Energy

Marathon Petroleum

Banco Santander

Total

Fund’s top buys from October 2018 to March 2019 include French energy giant Total.

Signature Select Canadian Fund’s Top Buys

Abbott Labs

Johnson & Johnson

Eli Lilly

Medtronic

Merck

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

The 10 Biggest Healthcare Stocks

Some Wall Street analysts are seeing coverage restrictions for $2.1 million gene therapy Zolgensma as a negative, but most of these restrictions are logical and no big deal

Novartis' Struggle With Payers Over Zolgensma Is Overblown

Rogers

Bristol-Myers

Gilead Sciences

Novo Nordisk

Sanofi

Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

The Top 10 Biotechnology Companies (JNJ, ROG.VX)

AbbVie

Bayer AG

GlaxoSmithKline

Roche Holding AG

SPDR S&P Pharmaceuticals ETF

"We're working on it right now a favored nations clause where we pay the lower nation's price is, like Canada," President Donald Trump tells reporters.

Trump says administration preparing an executive order on drug prices

Novartis is in the process of significantly improving product mix, through strategic divestitures.

Novartis: A Transformation Story Not To Miss In 2019

Alexion Pharma

Novelion Therapeutics

Spark Therapeutics

Spectrum Pharma

The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers.

The 5 Most Expensive Drugs In US: What You Should Know

Celgene

These follow-on drugs are on a path to upend the current standards of care.

3 Drugs Under FDA Review With Blockbuster Potential

NVS vs. NVO: Which Stock Is the Better Value Option?

NVS or NVO: Which Is the Better Value Stock Right Now?

Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

Novartis achieved the primary and secondary endpoints for the phase 3 QUARTZ study using QMF149 to treat patients with asthma.

Novartis Makes Substantial Pipeline Progress On A Couple Of Fronts

News for Novartis Stock (NVS)